ORT LAUDERDALE, FL — May 8, 2002 —
Switching to Xalatan® (latanoprost ophthalmic solution) once daily from monotherapy with other medications, including prostaglandin derivatives, for open angle glaucoma or ocular hypertension resulted in improved or maintained intraocular pressure (IOP) control, according to new data presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Fort Lauderdale.
Mean IOP in the 825 patients who completed the study improved by 3.0+/-3.4 mmHg after switching from another medication to six weeks treatment with Xalatan. The study also found low discontinuation rates (3.0%) of Xalatan due to adverse events over the treatment period.
“Xalatan is an appropriate choice when considering a change in glaucoma medication, since it consistently lowered IOP in these patients,” said Dr. TJ Zimmerman, University of Louisville, Louisville, KY. “A good adverse event profile may help improve patient compliance.” Study participants switched to Xalatan because they or their physician were not satisfied with previous monotherapy due to lack of efficacy, adverse events, inconvenience or cost.
Of the 599 patients who switched to Xalatan due to inadequate IOP control, 83 percent had >1 mmHg further reduction in IOP. Of the 139 patients who switched to Xalatan due to adverse events, 90 percent experienced resolution of the adverse event and maintained IOP control. 67 percent of the 150 patients who switched due to non-compliance, inconvenience, or cost of previous therapy experienced >1 mmHg reduction in IOP after switching.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!